Business
INOVIO Reports First Quarter 2020 Financial Results; Provides Business Update
- U.S. Phase 1 clinical trial for COVID-19 vaccine candidate INO-4800 completed enrollment with 40 healthy volunteers; preliminary results expected in late
About this update from Inovio Pharmaceuticals, Inc.
[{"type":"text","content":"- U.S. Phase 1 clinical trial for COVID-19 vaccine candidate INO-4800 completed enrollment with 40 healthy volunteers; preliminary results expected in late June\n - Phase 2/3 efficacy trial for INO-4800 to start this summer upon regulatory approval\n - Preclinical data manuscript for INO-4800 accepted for publication in Nature Communications; Several animal challenge studies currently ongoing\n - Additional clinical trials for INO-4800 in China and South Korea to start this summer\n - Positive interim data reported for VGX-3100 in Phase 2 clinical trials in precancerous anal and vulvar dysplasias\n - INO-3107 advances to Phase 1/2 clinical trial to treat rare, orphan disease recurrent respiratory papillomatosis (RRP)\n - 12-month overall survival efficacy data from INO-5401 in GBM to be presented at the American Society of Clinical Oncology (ASCO20)\n Investor Call at 4:30 PM ET\n\n\nPLYMOUTH MEETING, Pa., May 11, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to protect and treat people from infectious diseases, cancer, and diseases associated with HPV, today reported financial results for the quarter ended March 31, 2020. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Time today to discuss financial results and provide a general business update, including the company's development of INO-4800, one of the leading COVID-19 vaccine candidates currently in U.S. Phase 1 clinical trials. \nINOVIO's President and Chief Executive Officer Dr. J. Joseph Kim said, \"INOVIO had a very productive first quarter, laying the foundation for a transformative year for the company. Our recent and ongoing clinical developments across all of our programs continue to demonstrate the differentiating value and broad applicability of our DNA medicines platform. When the COVID-19 pandemic emerged in early January, INOVIO was able to leverage its DNA medicines platform and early funding from CEPI to be one of the first companies to advance a vaccine candidate for COVID-19 into a Phase 1 clinical trial. INOVIO's dedicated team of vaccine developers was able to quickly build and expand a global coalition of collaborators, partners, manufacturers, and funders to advance the INO-4800 program. \n\"Most importantly, while safely con...